Skip to main content



04-01-2019 | Oncology | News | Article

Atezolizumab, larotrectinib approvals announced by FDA

More information on use of these agents here

Preschool weight gain confers highest risk for teenage obesity

Endocrine Society updates 21-hydroxylase deficiency CAH guidelines

Latest GeNeSIS data confirm rhGH efficacy and long-term safety profile

Complications common in phenotypically normal male 45,X/46,XY patients

12-09-2018 | Leukaemia | News | Article

Levofloxacin reduces bacteremia during chemotherapy for childhood leukemia

Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.

11-09-2018 | Leukaemia | News | Article

Maternal hormonal contraceptive use linked to childhood non-lymphoid leukemia risk

The use of hormonal contraceptives just before and during pregnancy may significantly increase the risk for childhood non-lymphoid leukemia, Danish researchers report.

Mental, motor benefits accrue in Prader–Willi syndrome over longer-term GH treatment

Ethnicity influences reversibility of dysglycaemia in obese children

Concerns of Silver–Russell syndrome patients extend beyond height

Endocrine Society guideline focuses on childhood cancer survivors

Comorbidities account for increased mortality rate in children with central congenital hypothyroidism

Early insulin does not slow beta cell decline in youth with type 2 diabetes

21-06-2018 | ASCO | Main feed | News

Maintenance therapy boosts high-risk pediatric rhabdomyosarcoma survival

A significant overall survival benefit with the use of maintenance chemotherapy has been demonstrated by the RMS2005 trial of children who have completed standard treatment for high-risk, nonmetastatic rhabdomyosarcoma.

01-06-2018 | Oncology | News | Article

Adding nelarabine plus escalating methotrexate boosts pediatric, young adult T-ALL outcomes

The addition of nelarabine and an escalating dose of methotrexate to a standard chemotherapy regimen has achieved the best ever survival outcomes for children and young adults with a new diagnosis of T-cell acute lymphoblastic leukemia who are at risk for recurrence, researchers say.

Delays to growth hormone treatment initiation persist in Europe

Repurposed insulin pump for PTH infusion an option for treatment-resistant paediatric hypoparathyroidism

13-03-2018 | Oncology | News | Article

Data further highlight link between childhood cancer and long-term CVD risk

Young adult survivors of childhood cancer are at increased risk for cardiovascular disease, which develops earlier than in the general population, German study findings confirm.

07-03-2018 | Oncology | News | Article

Dasatinib confirmed as pediatric chronic phase CML option

The tyrosine kinase inhibitor dasatinib is effective and well tolerated as a first- or second-line therapy for children with chronic myeloid leukemia in the chronic phase, research confirms.

26-02-2018 | Oncology | News | Article

TNF inhibitor use may not increase pediatric malignancy risk

Children with autoimmune disorders have an increased cancer risk relative to the general population, but this risk appears to not be exacerbated by tumor necrosis factor inhibitor use, suggests an analysis of US administrative claims data.